High-dose immunoglobulin therapy for Guillain-Barré syndrome in Japanese children

Pediatrics International

Volumn 45, Issue 5, 2003, Pages 543-549

  Yata, Junichi ^a  

^a JISSEN WOMEN'S UNIVERSITY   (Japan)

Author keywords

Childhood; Guillain Barr syndrome; Intravenous immunoglobulin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN; IMMUNOGLOBULIN;

ARTICLE; ASEPTIC MENINGITIS; BLOOD TOXICITY; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHILIA; FEMALE; FEVER; GOOD GENERAL CONDITION; GRANULOCYTOPENIA; GUILLAIN BARRE SYNDROME; HEADACHE; HEMOGLOBINEMIA; HUMAN; IMMUNOTHERAPY; JAPAN; LEUKOPENIA; LIVER TOXICITY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; OUTCOMES RESEARCH; PEDIATRICS; PLEOCYTOSIS; PRIORITY JOURNAL; RETICULOCYTOSIS; SCALE UP; TREATMENT OUTCOME; VOMITING;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS, INTRAVENOUS; JAPAN; MALE;

EID: 0242408399     PISSN: 13288067     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-200X.2003.01768.x     Document Type: Article

References (32)

1. Hirano Y, Osawa M, Ohya T et al. Guillain-Barré syndrome in children: questionnaire survey on therapies and clinical outcomes. Shonika Rinsyo (Tokyo) 2000; 53: 77-85 (in Japanese).
2. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology 1993; 43: 872-5.
3. Castro LHM, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993; 43: 1034-6.
4. Asbury AK. New concepts of Guillain-Barré syndrome. J. Child Neurol. 2000; 15: 183-91.
5. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome - part 1. Muscle Nerve 1995; 18: 137-53.
6. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible models of action of IVIg. J. Autoimmun. 1993; 6: 683-9.
7. Rostami AM. Pathogenesis of immune-mediated neuropathies. Pediatr. Res. 1993; 33 (Suppl. 1): S90-S94.
8. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulin (IVIG) in the treatment of autoimmune diseases. Clin. Exp. Immunol. 1991; 86: 192-8.
9. Hughes RA, Raphaël JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford Update Software Ltd, 2001.
10. Reisin RC, Pociecha J, Rodriguez E, Massaro ME, Arroyo HA, Fejerman N. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr. Neurol. 1996; 14: 308-12.
11. Soueidan SA, Dalakas MC. Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Pediatr. Res. 1993; 33 (Suppl.): S95-S100.
12. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 1990; 27 (Suppl. 1): S21-S24.
13. Van der Meche FGA, Schmitz PIM. Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N. Engl. J. Med. 1992; 326: 1123-9.
14. Plasma exchange/Sandoglobulin Guillain-Barré syndrome trial group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349: 225-30.
15. Medical Research Council. Aids to the examination of the peripheral nervous system. Medical Research Council Memorandum no. 45 (superseding War Memorandum no. 7). Her Majesty's Stationery Office, London, 1976: 1-62.
16. Domen K. Functional Independence Measure (FIM). Sogo Rehabilitation 1990; 18: 627-9 (in Japanese).
17. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2: 750-3.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Statist. Assoc. 1958; 53: 457-81.
19. Hughes RA. The management of Guillain-Barré syndrome. Hosp. Pract. 1992; 30: 107-25.
20. Thorton CA, Griggs RC. Plasma exchange and intravenous immunoglobulin treatment of neuromuscular diseases. Ann. Neuro. 1994; 35: 260-8.
21. NIH Consensus Development. The utility of therapeutic plasmapheresis for neurological disorders. JAMA 1986; 256: 1333-7.
22. Shahar E, Murphy EG, Roifman CM. Benefit of intravenously administrated immune serum globulin in patients with Guillain-Barré syndrome. J. Pediatr. 1990; 116: 141-4.
23. Hughes RA, van der Meché FGA. Corticosteroids for treating Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford Update Software Ltd, 2000.
24. Singhi SC, Jayshree M, Singhi P, Banerjee S, Prabhakar S. Intravenous immunoglobulin in very severe childhood Guillain-Barré syndrome. Ann. Trop. Paediatr. 1999; 19: 167-74.
25. Saito T, Arimura K, No M. Epidemiological national survey of Guillain-Barré syndrome / Debrief report of the first questionnaire survey. In: Specified Diseases of Ministry of Health and Welfare, Immune Diseases of the Nervous System Surveillance Study Section Meeting Research Report of 1998. Japanese Ministry of Health and Welfare, Tokyo. 1999; 59-60.
26. Kanra G, Ozon A, Vajsar J et al. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Eur. J. Pediatr. Neurol. 1997; 1: 7-12.
27. Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990; 40: 1900-2.
28. Mouthon L, Kaveri SV, Spalter SH, Lacroix-Desmazes S, Lefranc C, Desai R et al. Mechanisms of action of intravenous immune globulin in immune-mediated diseases. Clin. Exp. Immunol. 1996; 104 (Suppl. 1): 3-9.
29. Abd-Allah SA, Jansen PW, Ashwal S, Perkin RM. Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome. J. Child Neurol. 1997; 12: 376-80.
30. Sater RA, Rostami A. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin. Neurology 1998; 51: S9-S15.
31. Dalakas MC. Intravenous immune globulin therapy for neurologic diseases. Ann. Intern. Med. 1997; 126: 721-30.
32. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann. Intern. Med. 1994; 121: 259-62.